We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Alexion Pharmaceuticals, Inc (ALXN) is a leading biotechnology business with stocks listed in the US. It opened the day at US$178.89 after a previous close of US$179.97. During the day the price has varied from a low of USD178.5 to a high of USD181.54. The latest price was USD180.69 (25 minute delay). Alexion Pharmaceuticals is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Alexion Pharmaceuticals
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Alexion Pharmaceuticals. Find the share by name or ticker symbol: ALXN. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alexion Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$177.12, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Alexion Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Alexion Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Alexion Pharmaceuticals key stats
- Compare share trading platforms
- Is Alexion Pharmaceuticals stock a buy or sell?
- Alexion Pharmaceuticals performance over time
- Can I short Alexion Pharmaceuticals shares?
- Is Alexion Pharmaceuticals suitable for ethical investing?
- Are Alexion Pharmaceuticals shares over-valued?
- Alexion Pharmaceuticals's financials
- How volatile are Alexion Pharmaceuticals shares?
- Does Alexion Pharmaceuticals pay a dividend?
- Have Alexion Pharmaceuticals shares ever split?
- Other common questions
Alexion Pharmaceuticals share priceUse our graph to track the performance of ALXN stocks over time.
Alexion Pharmaceuticals shares at a glance
|52-week range||US$99.91 - US$183.05|
|50-day moving average||US$174.9157|
|200-day moving average||US$158.1147|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$3.081|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Alexion Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Alexion Pharmaceuticals price performance over time
|1 month (2021-05-21)||1.67%|
|3 months (2021-03-19)||19.71%|
|6 months (2020-12-18)||15.27%|
|1 year (2020-06-19)||51.40%|
|2 years (2019-06-20)||40.25%|
|3 years (2018-06-20)||45.11%|
|5 years (2016-06-20)||45.76%|
Is Alexion Pharmaceuticals under- or over-valued?
Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alexion Pharmaceuticals's P/E ratio
Alexion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Alexion Pharmaceuticals shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Alexion Pharmaceuticals's PEG ratio
Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1581. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Alexion Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Alexion Pharmaceuticals's EBITDA
Alexion Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3.3 billion.
The EBITDA is a measure of a Alexion Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Alexion Pharmaceuticals financials
|Revenue TTM||US$6.3 billion|
|Operating margin TTM||47.41%|
|Gross profit TTM||US$5.5 billion|
|Return on assets TTM||10.08%|
|Return on equity TTM||4.43%|
|Market capitalisation||US$39.9 billion|
TTM: trailing 12 months
Shorting Alexion Pharmaceuticals shares
There are currently 8.5 million Alexion Pharmaceuticals shares held short by investors – that's known as Alexion Pharmaceuticals's "short interest". This figure is 9.4% down from 9.3 million last month.
There are a few different ways that this level of interest in shorting Alexion Pharmaceuticals shares can be evaluated.
Alexion Pharmaceuticals's "short interest ratio" (SIR)
Alexion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alexion Pharmaceuticals shares currently shorted divided by the average quantity of Alexion Pharmaceuticals shares traded daily (recently around 2.0 million). Alexion Pharmaceuticals's SIR currently stands at 4.24. In other words for every 100,000 Alexion Pharmaceuticals shares traded daily on the market, roughly 4240 shares are currently held short.
However Alexion Pharmaceuticals's short interest can also be evaluated against the total number of Alexion Pharmaceuticals shares, or, against the total number of tradable Alexion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alexion Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Alexion Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0384% of the tradable shares (for every 100,000 tradable Alexion Pharmaceuticals shares, roughly 38 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alexion Pharmaceuticals.
Find out more about how you can short Alexion Pharmaceuticals stock.
Alexion Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alexion Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Alexion Pharmaceuticals's total ESG risk score
Total ESG risk: 28.21
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alexion Pharmaceuticals's overall score of 28.21 (as at 12/31/2018) is pretty good – landing it in it in the 26th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Alexion Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Alexion Pharmaceuticals's environmental score
Environmental score: 8.12/100
Alexion Pharmaceuticals's environmental score of 8.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Alexion Pharmaceuticals's social score
Social score: 17.78/100
Alexion Pharmaceuticals's social score of 17.78 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Alexion Pharmaceuticals's governance score
Governance score: 15.31/100
Alexion Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Alexion Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Alexion Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Alexion Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||28.21|
|Total ESG percentile||26.48|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
|Level of controversy||2|
Alexion Pharmaceuticals share dividends
We're not expecting Alexion Pharmaceuticals to pay a dividend over the next 12 months.
Have Alexion Pharmaceuticals's shares ever split?
Alexion Pharmaceuticals's shares were split on a 2:1 basis on 22 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alexion Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alexion Pharmaceuticals shares which in turn could have impacted Alexion Pharmaceuticals's share price.
Alexion Pharmaceuticals share price volatility
Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as US$99.91 up to US$183.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alexion Pharmaceuticals's is 1.281. This would suggest that Alexion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alexion Pharmaceuticals overview
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Frequently asked questions
More guides on Finder
THE ICONIC x Finder: Huge 30% off sale + 5 things to shop right now
THE ICONIC's massive sale is exclusive to Finder members and applies to over 40,000 must-have items.
Why the BHP, Rio and FMG share prices are rising
Shares in mining giants BHP, Rio Tinto and Fortescue Metals have climbed between 10%-16% in the last 6 months.
Finder Daily Deals: The 5 best online deals in Australia today
Today's best Finder Daily deals include: $1,000 off Dell gaming laptops, 30% off kids toys, win $10,000 with Optus.
eBay EOFY sales: Best deals from Apple, KitchenAid and more
Score up to 65% off best-selling products with these top end of financial year offers.
Thinking about teeth aligners? Here’s how to make them more affordable
SPONSORED: Perfect teeth could be in closer reach than you think.
Your first look at the Billie Eilish x Air Jordan 1 sneaker collab
Featuring Billie's signature shade, here's what you need to know if you want to cop these kicks.
Amazon Prime Day 2021: Don’t miss these deals on 21 June
Amazon Prime Day is returning to Australia in the first half of 2021. Here are six online deals you need to know about.
How to buy TitanSwap (TITAN) in Australia
This guide will show you step-by-step instructions on how to buy the TitanSwap (TITAN) token as well as a list of exchanges you can trade it on.
Canterbury Bulldogs vs St George Illawarra Dragons NRL: Start time and watch free
The one-win Bulldogs return after a bye, hopefully refreshed and ready to meet the Dragons.
NSW first home owners tax reform offers 25K grants
First home buyers in NSW could be given up to $25,000 towards their first home purchase – find out if you're eligible.
Ask an Expert